Dr Reddy's, Gilead enter licensing pact for investigational COVID drug Remdesivir
Dr. Reddy’s will receive technology transfer from Gilead for the manufacturing of this drug.
Hyderabad and Princeton: Dr. Reddy's Laboratories Ltd. recently announced that it has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. that will grant Dr. Reddy's the right to register, manufacture and sell Gilead's investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India.
Dr. Reddy's will receive technology transfer from Gilead for the manufacturing of this drug. Dr. Reddy's would need to do the manufacturing scale-up and obtain regulatory approval for marketing of this drug in respective countries.
Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (USFDA) to treat Covid-19.
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, committed to providing affordable and innovative medicines for healthier lives.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
The Company's markets include – USA, India, Russia & CIS countries, and Europe.